Adeno-associated virus 9–mediated Cdk5 inhibitory peptide reverses pathologic changes and behavioral deficits in the Alzheimer’s disease mouse model

Neurodegeneration-Like Pathological and Behavioral Changes in an AAV9-Mediated p25 Overexpression Mouse Model

(2016) Xiao Zhou et al.   JOURNAL OF ALZHEIMERS DISEASE

Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells

(2016) Steven F. Merkel et al.   JOURNAL OF NEUROCHEMISTRY

Cdk5/p25 specific inhibitory peptide TFP5 rescues the loss of dopaminergic neurons in a sub-acute MPTP induced PD mouse model

(2016) Qishan Zhang et al.   NEUROSCIENCE LETTERS

Transient enhancement of proliferation of neural progenitors and impairment of their long-term survival in p25 transgenic mice

(2016) Donghua Zou et al.   Oncotarget

Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9

(2016) Jonathan Dashkoff et al.   Molecular Therapy-Methods & Clinical Development

Anxiety Symptoms in Amnestic Mild Cognitive Impairment Are Associated with Medial Temporal Atrophy and Predict Conversion to Alzheimer Disease

(2015) Linda Mah et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Glibenclamide Improves Survival and Neurologic Outcome After Cardiac Arrest in Rats*

(2015) Kaibin Huang et al.   CRITICAL CARE MEDICINE

Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson’s disease

(2015) BK. Binukumar et al.   MOLECULAR BIOLOGY OF THE CELL

Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level

(2015) Katherine R Sadleir et al.   Molecular Neurodegeneration

Overcoming Insulin Insufficiency by Forced Follistatin Expression in β -cells of db/db Mice

(2015) Chunxia Zhao et al.   MOLECULAR THERAPY

Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer’s mice

(2014) John F. Castro-Alvarez et al.   Frontiers in Aging Neuroscience

An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models

(2014) Catherine Gérard et al.   Molecular Therapy-Methods & Clinical Development

Specific Inhibition of p25/Cdk5 Activity by the Cdk5 Inhibitory Peptide Reduces Neurodegeneration In Vivo

(2013) J. R. Sundaram et al.   JOURNAL OF NEUROSCIENCE

Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease

(2013) Kenghoe Lok et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice

(2012) Varsha Shukla et al.   FASEB JOURNAL

Cdk5/p25-Induced Cytosolic PLA2-Mediated Lysophosphatidylcholine Production Regulates Neuroinflammation and Triggers Neurodegeneration

(2012) J. R. Sundaram et al.   JOURNAL OF NEUROSCIENCE

Adeno-associated virus (AAV) gene therapy for neurological disease

(2012) Marc S. Weinberg et al.   NEUROPHARMACOLOGY

Cyclin-Dependent Kinases in Brain Development and Disease

(2011) Susan C. Su et al.   Annual Review of Cell and Developmental Biology

Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice

(2010) Niels J. Rupp et al.   NEUROBIOLOGY OF AGING

Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models

(2010) Bénédicte Menn et al.   PLoS One

Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer’s disease

(2009) Christopher J. Helal et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Neurodegeneration and Neuroinflammation in cdk5/p25-Inducible Mice

(2008) David Muyllaert et al.   AMERICAN JOURNAL OF PATHOLOGY